Navigation Links
Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer

ews release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen's Form 10-K for the year ended December 31, 2006, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.

Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify side effects or manufacturing problems with Amgen's products after they are on the market. In addition, sales of Amgen's products are affected by the av
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
(Date:12/15/2009)... Inc. (Nasdaq: BLUD ), a global leader in ... today announced that it will release its fiscal 2010 ... the market close. The Company will host a conference ... (Eastern Time) to discuss the results. ,, ... by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also access ...
(Date:12/15/2009)... Robbins & Myers, Inc. (NYSE: ... for its fiscal 2010 first quarter ending November 30, ... 2010. A live webcast is scheduled for ... Peter C. Wallace, President and Chief Executive ... Financial Officer, will be discussing the Company,s performance and ...
(Date:12/15/2009)... U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ... no, and 1 abstention that AstraZeneca has established sufficient ... use of CRESTOR® (rosuvastatin calcium) in individuals meeting the ... to 50 years, women greater than or equal to ... hsCRP greater than or equal to 2.0 mg/L; Triglycerides ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 1Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 2Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 3Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 1Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 2Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 3Lots of Schoolkids Squint to See Chalkboard 53528 1
(Date:12/15/2009)... NAPA, Calif., Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences ... healthy aging, today announced that shareholders had approved all three resolutions that the Company had ... were as follows: , , Description of ... Votes ... For ...
(Date:12/15/2009)... Lady of Lourdes Health Care Services Inc., the parent ... pay the United States $7.95 million to resolve allegations ... today. The two hospitals are Our Lady of Lourdes ... Center of Burlington County (LMC) in Willingboro, N.J. ... by a whistleblower, Tony Kite, in 2005. The lawsuit ...
(Date:12/15/2009)... doses have lower strength than needed for protection, CDC ... 800,000 children,s doses of H1N1 swine flu vaccine have ... have lost some potency, federal health officials said Tuesday. ... and Prevention, the company,s routine testing of the vaccine ... found that four batches had lower than required potency ...
(Date:12/15/2009)... 15 4R Systems, Inc., a leading ... which help retailers significantly increase profits by optimizing ... today that The Vitamin Shoppe has been utilizing ... store and DC inventory solutions have helped us ... in-stocks over the last two years," said Tony ...
(Date:12/15/2009)... North American application activity for individually underwritten life ... the MIB Life Index(SM) . Solid ... three months have lifted year-to-date (YTD) figures from ... at November,s close, -0.1%. "It is clear ... available from life insurance," says Stacy Gill, MIB ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3
... 8 Sector 10, Inc. (OTC,Bulletin Board: SECT; Frankfurt: ... milestone schedule to start this month with Syptec Internet,Services ... The,deployment is being largely based on private digital alarm ... and is set to scale as large,as 50-53,000 concurrent ...
... almost fivefold, German study finds , , TUESDAY, July 8 ... the more likely it will spread or reoccur, according ... research in the August edition of The Lancet ... tumor thickness were almost five times more likely to ...
... one of the major challenges of the 21st century ... health care systems. Recently, common pathways of the two ... dementia have been suggested. Today there is tremendous interest ... step in the disease cascade or even prevent the ...
... ANGELES, July 8 , WHAT: City of ... 8th,annual La Gota de la Vida campaign to ... treatment institution for cancer and other,life-threatening diseases. The ... National Bone Marrow Registry. This year,s activities,will include ...
... 8 The VHA,Foundation, a foundation focused on ... and the National Business Group on Health (NBGH), ... employers,devoted exclusively to finding innovative solutions to health ... award that recognizes health,systems who are taking a ...
... & Johnson,will host a conference call for financial ... 15, 2008, to review second-quarter results. Dominic,Caruso, Vice ... Vice President, Investor Relations, will host the call., ... the broadcast by,visiting the Company,s website at ...
Other Medicine News:Health News:Announcement Outlines 36 Month Custom Deployment Contract With Potential Revenues Reaching $30 Million Dollars 2Health News:Paul Rodriguez, Voces Del Rancho and More to Be Honored at the 8th Annual Angels of Hope Awards, July 12 2Health News:Two National Health Organizations to Recognize the Nation's Best Health Systems for Patient Safety Leadership 2Health News:Two National Health Organizations to Recognize the Nation's Best Health Systems for Patient Safety Leadership 3
... The Bledsoe Tenderfoot™ Boot features a ... Density technology used in our Conformer boots. ... pre-ulcerative foot conditions in sensate patients, plantar ... or callouses, or any other foot condition ...
... is designed as a flexible and attractive alternative ... mid-foot area and also for second and third ... than the Bledsoe Hi-Top Boot but offers similar ... designed for range of motion from 20 degrees ...
... Diabetic Boot features a fully enclosed thick, ... unique auto-molding innersole which embeds into a ... aluminum shelled walking boot. This unique Automold™ ... distribute body weight across the entire bottom ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: